

Immune Modulator

Rilzabrutinib (WAYRILZ)

Adult Table

MEDICATION NAME:	RILZABRUTINIB BRAND: WAYRILZ
HOW IS IT GIVEN:	Oral tablet.
HOW DOES IT WORK:	A multi-immune modulator, inhibiting the cell signaling enzyme Bruton's tyrosine kinase (BTK), thus decreasing platelet autoantibody production and platelet destruction via macrophages in the spleen and liver
COMMON DOSING REGIMENS:	400 mg orally twice daily with or without food. There are no dosage adjustments for safety or effectiveness.
COMMON SIDE EFFECTS:	Most common adverse reactions (incidence $\geq 10\%$) were diarrhea, nausea, headache, abdominal pain, and COVID-19.
RARE BUT SERIOUS SIDE EFFECTS:	Serious Infections, hepatotoxicity including drug-induced liver injury (DILI)
TYPICAL TIME TO RESPONSE:	2-5 weeks.
LIKELIHOOD OF INITIAL RESPONSE:	Approximately 64% of patients attain an initial platelet response (count of $30\text{-}50 \times 10^9/\text{L}$ and doubling from baseline or $50 \times 10^9/\text{L}$ or greater) at week 12.
LIKELIHOOD OF LONG-TERM RESPONSE (3-5 YEARS):	The prevalence of sustained remission off treatment has not yet been established.

OTHER CONSIDERATIONS:	<p>Before taking WAYRILZ, tell your healthcare provider about all of your medical conditions, including if you:</p> <ul style="list-style-type: none">• are pregnant or plan to become pregnant. WAYRILZ may harm your unborn baby. If you are able to have a baby, your healthcare provider will do a pregnancy test before starting treatment with WAYRILZ. females who are able to become pregnant should use effective birth control (contraception) during treatment with WAYRILZ and for 1 week after the last dose.• are breastfeeding or plan to breastfeed. It is not known if WAYRILZ passes into your breast milk. Do not breastfeed during treatment with WAYRILZ and for at least 1 week after the last dose. <p>If you take an antacid or H2 blocker medicine, take your dose of WAYRILZ at least 2 hours before taking an antacid or H2 blocker medicine. If you take a Proton Pump Inhibitor (PPI) medicine, talk to your healthcare provider.</p>
-----------------------	---

References

1. David J. Kuter, et. al.; Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study. Blood 2025; 145 (24): 2914–2926. doi: <https://doi.org/10.1182/blood.2024027336>
2. Kuter, D. J., & Ghanima, W. (2025). Evaluating rilzabrutinib in the treatment of immune thrombocytopenia. Immunotherapy, 1–16. <https://doi.org/10.1080/1750743X.2025.2545170>
3. Wayrilz package insert: <https://products.sanofi.us/wayrilz/wayrilz.pdf>
4. Wayrilz website: www.wayrilz.com